Retraction Casts Doubt on Timing Effects of Immunotherapy.

A retracted trial undermines the first randomized evidence on checkpoint inhibitor dosing timing, casting doubt on the influence of circadian biology on immunotherapy efficacy.

• Why it matters: Understanding whether circadian biology affects immunotherapy outcomes is crucial for optimizing treatment schedules, but trust in key evidence has been compromised by this retraction.
• What they did: Researchers are re-evaluating existing data from the trial and other sources to determine what conclusions about dosing timing and circadian effects remain valid.
• The result: This reassessment will clarify the role of circadian biology in immunotherapy, guiding future research and clinical practice despite the setback from the discredited trial.